Pelthos Therapeutics Inc. (NASDAQ:PTHS) Struggles with Capital Efficiency Compared to Peers
Financial Modeling Prepยท2025-11-18 17:00
Core Insights - Pelthos Therapeutics Inc. is struggling to generate returns that exceed its cost of capital, with a ROIC of -21.33% compared to a WACC of 24.01%, resulting in a ROIC to WACC ratio of -0.89 [1][2][5] - The negative ROIC indicates inefficiency in capital utilization, raising concerns for investors regarding sustainable growth [2][5] - In comparison, Azitra, Inc. and Silexion Therapeutics Ltd. exhibit even worse capital efficiency, with ROICs of -494.84% and -363.40% respectively, against much lower WACCs [3][5] - Conversely, Longevity Health Holdings Inc. demonstrates strong performance with a positive ROIC of 185.17% and a WACC of 5.43%, indicating effective capital utilization and growth potential [4][5]